Zahreddine, Rana Davezac, Morgane Smirnova, Natalia F Buscato, Melissa LHUILLIER, EMELINE Lupieri, Adrien Solinhac, Romain Vinel, Alexia Vessières, Emilie Henrion, Daniel
...
Rationale: Tamoxifen prevents the recurrence of breast cancer and is also beneficial against bone demineralization and arterial diseases. It acts as an Estrogen Receptor (ER) α antagonist in ER-positive breast cancers, whereas it mimics the protective action of 17β-estradiol (E2) in other tissues such as arteries. However, the mechanisms of these t...
Robinson, Anastasia G J Kanaan, Yasmine M Copeland, Robert L
Published in
Anticancer research
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer (BC) and lacks targeted therapy and alternate therapeutic combinations. There is a necessity to increase disease-free survival in patients particularly within the first 5 years of diagnosis. 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone (Z285), a novel 1,4 naphthoquin...
Jabłoński, Krzysztof Kurek, Łukasz Żukowski, Maciej Data-Jabłońska, Natalia Żukowska, Karolina Milewska, Anna J Lipka, Aleksandra Jóźwik, Marcin
Published in
Journal of clinical medicine
Tamoxifen is a commonly used selective estrogen receptor modulator applied in the treatment for breast cancer. However, in the endometrium, Tamoxifen stimulates tissue growth, cellular transformation, the migration of the cells, and metastatic potential in endometrial cancer. Considering that uterine cancer is the most common neoplasm of the reprod...
Shemer, Anat Scheyltjens, Isabelle Frumer, Gal Ronit Kim, Jung-Seok Grozovski, Jonathan Ayanaw, Serkalem Dassa, Bareket Van Hove, Hannah Chappell-Maor, Louise Boura-Halfon, Sigalit
...
Published in
Immunity
Microglia, the resident macrophages of the brain parenchyma, are key players in central nervous system (CNS) development, homeostasis, and disorders. Distinct brain pathologies seem associated with discrete microglia activation modules. How microglia regain quiescence following challenges remains less understood. Here, we explored the role of the i...
Xu, Zhixiang Zhao, Dimeng Zheng, Xianyao Huang, Bin Xia, Xueshan Pan, Xuejun
Published in
Environmental toxicology
Tamoxifen was widely applied in the therapy of estrogen receptor (ER)-positive breast cancer. With the purpose of determining the potential impacts of quercetin on its effectiveness, MCF-7 cells were selected as the in vitro model and several cellular biological behaviors (ie, cell proliferation, migration, invasion, cycle, apoptosis, and oxidative...
Mangla, Bharti Neupane, Yub R Singh, Archu Kumar, Pankaj Shafi, Sadat Kohli, Kanchan
Published in
Nanomedicine (London, England)
Aim: This study aims to load tamoxifen (TAM) and sulforaphane (SFN) into nanostructured lipid carriers (NLCs) to enhance their oral delivery. Materials & methods: TAM-SFN-NLCs were prepared using Precirol® ATO5 and Transcutol® HP, characterized and evaluated in vitro and ex vivo to assess the drug release profile and intestinal permeability, respec...
Chan, Karen Kar Loen Ngu, Siew Fei Chu, Mandy Man Yee Tse, Ka Yu Ngan, Hextan Yuen Sheung
Published in
Asia-Pacific journal of clinical oncology
To review the clinical use and the effectiveness of tamoxifen in patients with advanced or recurrent ovarian cancer. A retrospective review of clinical records was conducted in patients who received tamoxifen for the treatment of ovarian cancer between 2002 and 2016. We reviewed the clinical setting that it was given, duration of use, patients' tol...
Papadimitropoulou, Adriana Vellon, Luciano Atlas, Ella Steen, Travis Vander Cuyàs, Elisabet Verdura, Sara Espinoza, Ingrid Menendez, Javier A. Lupu, Ruth
Published in
International Journal of Molecular Sciences
Sustained HER2/HER3 signaling due to the overproduction of the HER3 ligand heregulin (HRG) is proposed as a key contributor to endocrine resistance in estrogen receptor-positive (ER+) breast cancer. The molecular mechanisms linking HER2 transactivation by HRG-bound HER3 to the acquisition of a hormone-independent phenotype in ER+ breast cancer is, ...
Kudela, Erik Samec, Marek Koklesova, Lenka Liskova, Alena Kubatka, Peter Kozubik, Erik Rokos, Tomas Pribulova, Terezia Gabonova, Eva Smolar, Marek
...
Published in
International Journal of Molecular Sciences
Breast cancer, which is the most common malignancy in women, does not form a uniform nosological unit but represents a group of malignant diseases with specific clinical, histopathological, and molecular characteristics. The increasing knowledge of the complex pathophysiological web of processes connected with breast cancercarcinogenesis allows the...
Menendez, Javier A. Mehmi, Inderjit Papadimitropoulou, Adriana Vander Steen, Travis Cuyàs, Elisabet Verdura, Sara Espinoza, Ingrid Vellon, Luciano Atlas, Ella Lupu, Ruth
...
Published in
International Journal of Molecular Sciences
HER2 transactivation by the HER3 ligand heregulin (HRG) promotes an endocrine-resistant phenotype in the estrogen receptor-positive (ER+) luminal-B subtype of breast cancer. The underlying biological mechanisms that link them are, however, incompletely understood. Here, we evaluated the putative role of the lipogenic enzyme fatty acid synthase (FAS...